Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron, a developer of biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, has appointed Karin Eastham to its board of directors. Ms Eastham will also serve as chair of the company's audit committee.
Subscribe to our email newsletter
Ms Eastham will join Geron’s existing board members: board chair Alexander Barkas, Edward Fritzky, Charles Homcy, Thomas Kiley, Patrick Zenner and Geron’s president and CEO, Thomas Okarma.
Ms Eastham currently serves on the boards of directors for several life science companies, including Amylin Pharmaceuticals, Illumina, and Genoptix. She most recently served as executive vice president and COO and a member of the board of trustees of the Burnham Institute for Medical Research.
Mr Okarma said: “I am pleased to welcome Ms Eastham to our board of directors. Karin brings to the board over 30 years of experience in the financial and operations management of life science companies and we look forward to her advice and counsel.”